Antidepressant & Psychiatric Medication Withdrawal Guides

Celexa has a moderate discontinuation profile similar to its single-enantiomer cousin Lexapro. The relatively long half-life smooths the washout, and most patients can taper without significant difficulty when the schedule is gradual.

Lexapro (escitalopram) has a moderate discontinuation profile - generally better-tolerated than Paxil or Effexor, but real symptoms still occur, especially after long-term use or rapid taper. Most patients can taper Lexapro without significant difficulty when the schedule is slow enough.

Luvox sits between the easy SSRIs (Prozac, Lexapro) and the difficult ones (Paxil) for discontinuation. The shorter half-life means symptoms emerge faster and feel more intense than with longer-acting SSRIs. Less commonly prescribed than Zoloft or Lexapro, so patient communities discussing withdrawal are smaller, but the pattern is real.

Paxil (paroxetine) is widely recognized as the SSRI with the most severe discontinuation syndrome, comparable to Effexor in difficulty. The short half-life, lack of an active metabolite, and significant anticholinergic activity combine to produce vivid withdrawal symptoms within a day of dose reduction. Many patients describe Paxil withdrawal as among the most physically uncomfortable medication-discontinuation experiences in psychiatry.

Prozac has the mildest discontinuation profile of the SSRIs because its active metabolite norfluoxetine essentially auto-tapers the patient over weeks after the last dose. Some patients can stop Prozac abruptly with no noticeable symptoms at all. This same property is why Prozac is sometimes used as a bridge for patients struggling to taper off short-half-life SSRIs or SNRIs.

Viibryd has a moderate discontinuation profile similar to other SSRIs with comparable half-lives. The 5-HT1A partial agonist activity does not appear to substantially alter the withdrawal pattern compared to pure SSRIs.

Zoloft has a moderate discontinuation profile, generally better tolerated than Paxil or Effexor but more pronounced than Prozac. Most patients can taper without significant difficulty when the schedule is gradual. Symptoms tend to be flu-like rather than the dramatic brain-zap-and-vertigo pattern seen with short-half-life agents.

Cymbalta (duloxetine) has one of the most challenging discontinuation profiles among the SNRIs, second only to Effexor. The combination of a short half-life and dual serotonergic-noradrenergic activity produces vivid withdrawal symptoms. Compounded difficulty: Cymbalta is only available in 20, 30, and 60 mg capsules, with no liquid formulation, which makes fine titration difficult during the final phase of tapering.

Effexor (venlafaxine) is widely recognized as having one of the most pronounced antidepressant discontinuation syndromes. The combination of a short half-life and dual serotonergic-noradrenergic activity means that even a single missed dose can produce symptoms; abrupt cessation reliably produces them. The XR (extended-release) formulation smooths peaks but does not change the underlying withdrawal physiology.

Fetzima (levomilnacipran) has a discontinuation pattern similar to other short-half-life SNRIs. Less commonly prescribed than Cymbalta or Effexor, so patient communities discussing withdrawal are smaller, but the same physiology applies.

Pristiq (desvenlafaxine) has a discontinuation profile similar to Effexor, of which it is the active metabolite. Most patients describe Pristiq withdrawal as slightly more manageable than Effexor, but the same short-half-life pattern applies and abrupt cessation produces a real withdrawal syndrome.

Savella (milnacipran) has a pronounced discontinuation pattern driven by its very short half-life. In the US it is FDA-approved for fibromyalgia rather than depression. Patients tapering Savella often experience a return of both fibromyalgia symptoms and the discontinuation syndrome itself, which can be hard to separate.

Auvelity is a newer FDA-approved antidepressant (2022) that combines an NMDA receptor antagonist (dextromethorphan) with an NDRI (bupropion). Discontinuation data is more limited than for older agents. Reported withdrawal patterns appear similar to bupropion alone given the bupropion component dominates the longer-term effects.

Remeron (mirtazapine) has a moderate discontinuation profile. The most distinctive aspect is rebound insomnia and increased anxiety, particularly in patients who were taking Remeron primarily for sleep. The relatively long half-life smooths the washout.

Trazodone has a mild discontinuation profile. Most outpatient use is at low doses (50-200 mg) for sleep rather than antidepressant doses (300-600 mg), and low-dose discontinuation is typically uneventful. Higher doses used for depression can produce a more notable withdrawal pattern.

Trintellix (vortioxetine) has a relatively mild discontinuation profile, helped substantially by its long half-life. Compared to SSRIs and especially SNRIs, withdrawal symptoms are less intense and less common. The FDA labeling does not require a tapering schedule for most patients, although a gradual reduction is still good practice.

Wellbutrin (bupropion) has a notably mild discontinuation profile compared to SSRIs and SNRIs. Because it works on dopamine and norepinephrine rather than serotonin, it does not produce the classic SSRI discontinuation syndrome (brain zaps, dizziness, GI distress). Most patients can taper Wellbutrin with little difficulty.

Amitriptyline (Elavil) has a notable discontinuation pattern dominated by anticholinergic rebound. Abrupt cessation can produce a flu-like cholinergic rebound (sometimes called "TCA discontinuation syndrome") that is distinct from the SSRI pattern. Most patients can taper without major difficulty when the schedule is gradual.

Clomipramine (Anafranil) has a moderate discontinuation profile that combines TCA cholinergic rebound with SSRI-pattern serotonergic withdrawal, because clomipramine is the most serotonergic of the TCAs. OCD return is the most clinically important phenomenon for patients tapering clomipramine.

Desipramine (Norpramin) has a milder discontinuation profile than the more sedating TCAs like amitriptyline because it has lower anticholinergic activity. Most patients can taper without significant difficulty.

Doxepin discontinuation depends heavily on dose. Low-dose use (3-6 mg, Silenor for sleep) produces minimal withdrawal. Higher antidepressant doses (75-300 mg) produce a TCA-pattern withdrawal with cholinergic rebound similar to amitriptyline.

Imipramine has a discontinuation pattern dominated by cholinergic rebound, similar to amitriptyline. Less commonly prescribed now than in the past. Most patients can taper without major difficulty when the schedule is gradual.

Nortriptyline (Pamelor) has a similar discontinuation pattern to amitriptyline but tends to be milder overall, in part because it has less anticholinergic activity. The cholinergic rebound syndrome is less pronounced. Most patients taper without significant difficulty.

Emsam (transdermal selegiline) has a milder discontinuation pattern than oral MAOIs at low doses because of its MAO-B selectivity. At higher doses the pattern resembles other MAOIs. Most patients tapering Emsam describe sleep changes and return of depression as the dominant experiences.

Marplan (isocarboxazid) has a discontinuation pattern similar to Nardil. Less commonly prescribed than Nardil or Parnate, and the same general MAOI considerations apply.

Nardil (phenelzine) has a discontinuation pattern that is pharmacologically benign compared to SSRIs, but the dietary restrictions ending and the gradual return of normal MAO function over 2 weeks produces its own pattern. Patients tapering MAOIs often describe sleep changes and the return of depression as the dominant experiences.

Parnate (tranylcypromine) has a discontinuation pattern similar to Nardil but with more amphetamine-like properties (tranylcypromine has structural similarity to amphetamines). Some patients describe a stimulant-like crash when stopping in addition to the gradual MAO normalization.

Ativan (lorazepam) has a substantial withdrawal pattern similar to Xanax, though the longer half-life makes the inter-dose withdrawal less pronounced. As with all benzodiazepines, abrupt cessation after chronic use carries seizure risk and tapering should be done under medical supervision.

Halcion (triazolam) has the shortest half-life of the commonly-prescribed benzodiazepines. This makes inter-dose withdrawal and rebound insomnia particularly pronounced. Chronic use is uncommon now, but for patients who do use it chronically, the withdrawal pattern can be intense given the rapid offset.

Klonopin (clonazepam) has a more gradual withdrawal pattern than Xanax or Ativan because of its long half-life, but the underlying severity is comparable for chronic users. The slower offset means symptoms emerge over days rather than hours, but the cumulative withdrawal burden is similar. Seizure risk applies the same as with other benzodiazepines.

Librium (chlordiazepoxide) has a withdrawal pattern similar to Valium given the long half-life and active metabolites. Less commonly used now for chronic anxiety; main current use is in alcohol withdrawal protocols. Same seizure risk applies for chronic users who stop abruptly.

Restoril (temazepam) is typically used at low doses for sleep rather than chronic anxiety, which makes the withdrawal pattern usually milder than Xanax or Ativan. Chronic use at higher doses produces a benzo-pattern withdrawal with the same seizure risk on abrupt cessation.

Valium (diazepam) has the most gradual withdrawal pattern of the commonly-prescribed benzodiazepines because of its very long half-life and multiple active metabolites. This is why diazepam is the standard bridge medication in the Ashton method for tapering shorter-acting benzodiazepines. Seizure risk with abrupt cessation still applies for chronic users.

Xanax (alprazolam) has one of the most severe withdrawal syndromes of any benzodiazepine, comparable to short-acting alcohol withdrawal. Abrupt cessation after chronic use can produce seizures, which is a medical emergency. The combination of high potency, short half-life, and rapid onset of action makes Xanax both the most popular and the most physically dependence-forming benzo. Tapering MUST be done under medical supervision.

Ambien (zolpidem) is technically not a benzodiazepine but acts on the same GABA-A receptor complex, and chronic use produces similar dependence. Withdrawal is dominated by rebound insomnia, often pronounced enough that patients return to the medication immediately. Seizure risk on abrupt cessation after long-term high-dose use is real, though less than with traditional benzodiazepines.

Belsomra (suvorexant) works by blocking orexin (a wake-promoting signal) rather than enhancing GABA like benzodiazepines and Z-drugs. It was designed to avoid the dependence and rebound seen with older hypnotics, and in studies it shows little physical withdrawal. The most common effect of stopping is mild, transient rebound insomnia.

Dayvigo (lemborexant) is in the same orexin-antagonist class as Belsomra and shares its low dependence potential. In studies it showed minimal rebound insomnia and no significant withdrawal syndrome on stopping. Because it is newer, individual data are limited, but the class behaves very differently from benzodiazepines and Z-drugs.

Lunesta (eszopiclone) has a slightly longer half-life than Ambien and a somewhat smoother discontinuation profile, but the same fundamental rebound-insomnia pattern applies. Chronic use produces dependence and stopping reliably produces rebound effects.

Daridorexant, the newest of the orexin-antagonist sleep medications, was designed with the dependence problems of older hypnotics in mind. In clinical trials it showed no meaningful withdrawal syndrome and minimal rebound insomnia after stopping, in contrast to benzodiazepines and Z-drugs (Ambien, Lunesta). The main thing people notice on stopping is the return of the original insomnia rather than a true withdrawal state.

Sonata (zaleplon) has the shortest half-life of the Z-drugs, which makes it less likely to produce next-day residual effects but more likely to produce middle-of-night awakening. Discontinuation is generally mild because chronic dependence is less common with such a short-acting agent.

Abilify (aripiprazole) has a relatively mild discontinuation profile compared to other atypicals, helped by its very long half-life. The clinically important concerns are the return of underlying psychiatric symptoms and, in rare cases, withdrawal dyskinesia (involuntary movements that emerge or worsen on discontinuation).

Caplyta (lumateperone) is a newer atypical antipsychotic used for schizophrenia and bipolar depression. Published data on its discontinuation syndrome specifically are limited, so guidance is extrapolated from the antipsychotic class as a whole: abrupt cessation can produce rebound symptoms, insomnia, and (less commonly) withdrawal dyskinesia. Taper rather than stop suddenly.

Clozapine (Clozaril) has one of the most serious discontinuation profiles in psychiatry. Abrupt cessation can produce rapid cholinergic rebound (the body reacting to loss of clozapine's strong anticholinergic effect) and rebound or "supersensitivity" psychosis that can be faster and more severe than the original illness. It must never be stopped abruptly except under specialist direction (for example, for a serious blood or cardiac adverse effect).

Fanapt (iloperidone) is used for schizophrenia. Its discontinuation profile follows the atypical class - insomnia, nausea, rebound symptoms, and possible withdrawal-emergent dyskinesia on abrupt cessation. As with starting, dose changes are handled gradually.

Geodon (ziprasidone) has a moderate discontinuation profile. The shorter half-life means rebound effects can emerge quickly. Less commonly prescribed than other atypicals but used for both schizophrenia and bipolar disorder.

Haldol (haloperidol) is a high-potency first-generation antipsychotic. Because it has little anticholinergic activity, cholinergic rebound is less prominent than with clozapine - but withdrawal-emergent dyskinesia and rebound psychosis are real risks on abrupt cessation. Taper rather than stop suddenly.

Invega (paliperidone) is used for schizophrenia and schizoaffective disorder. Oral discontinuation can produce insomnia, nausea, and rebound symptoms; abrupt cessation carries a meaningful relapse risk. The long-acting injectables decline slowly on their own, which blunts acute withdrawal but extends the timeline.

Latuda (lurasidone) has a moderate discontinuation profile. As with other antipsychotics, the clinically important concerns are return of underlying psychiatric symptoms and rare withdrawal dyskinesia.

Rexulti (brexpiprazole) has a mild discontinuation profile similar to Abilify, helped by its very long half-life. Return of underlying symptoms is the most clinically important concern.

Risperdal (risperidone) has a moderate discontinuation profile. The relatively short half-life of the parent drug and shorter overall washout means rebound effects can emerge more quickly than with longer-acting agents like Abilify or Vraylar.

Saphris (asenapine) is used for schizophrenia and bipolar I. Like other atypicals, abrupt discontinuation can produce insomnia, nausea, rebound symptoms, and occasionally withdrawal-emergent dyskinesia. A gradual taper is preferred.

Seroquel (quetiapine) has a notable discontinuation pattern dominated by rebound insomnia and anxiety, particularly in patients using it primarily for sleep. The relatively short half-life makes rebound effects emerge quickly. For psychiatric indications, relapse risk is the more clinically important concern.

Symbyax is unusual because you are stopping two drugs at once. The fluoxetine half is among the gentlest antidepressants to come off - its very long half-life means it tapers itself and rarely produces brain zaps or an abrupt discontinuation syndrome. The olanzapine half is the one that needs attention: stopping an antipsychotic can produce cholinergic rebound (nausea, sweating, insomnia, agitation) and, in susceptible patients, rebound symptoms of the underlying illness. Because Symbyax is approved specifically for bipolar depression and treatment-resistant depression, relapse of the mood disorder is the larger concern for many patients.

Vraylar (cariprazine) has the most gradual discontinuation profile of any antipsychotic because its active metabolite has an extraordinarily long half-life (1-3 weeks). Withdrawal effects emerge over weeks rather than days.

Zyprexa (olanzapine) has a moderate discontinuation profile. Rebound insomnia and anxiety are common in the first 1-2 weeks. Return of underlying psychiatric symptoms is the more clinically important long-term concern. Withdrawal dyskinesia, while uncommon, is recognized.

Depakote does not produce a classical withdrawal syndrome. As with other mood stabilizers and anticonvulsants, the clinically important risks on discontinuation are mood relapse in bipolar patients and seizure recurrence in epilepsy patients. Slow tapering is the standard.

Gabapentin (Neurontin) is prescribed widely - often off-label - for anxiety, sleep, and nerve pain, and physical dependence is now well documented, particularly above ~1800 mg/day or after prolonged use. Abrupt discontinuation can produce a withdrawal syndrome that resembles benzodiazepine or alcohol withdrawal, including, rarely, seizures. It should not be stopped abruptly.

Lamictal (lamotrigine) does not produce a classical withdrawal syndrome. The clinically important risks are: (1) seizure recurrence in patients taking lamotrigine for epilepsy, and (2) return of bipolar depression in patients taking it for mood stabilization. Abrupt cessation should be avoided in both populations.

Lithium has a unique discontinuation profile distinct from antidepressant or benzodiazepine withdrawal. The pharmacology doesn't produce a classical "withdrawal syndrome." The clinically important phenomenon is the risk of mania or rapid-cycling on discontinuation, particularly with abrupt cessation. Patients with bipolar disorder who stop lithium are at substantially elevated risk of relapse, sometimes more severe than their pre-treatment episodes.

Pregabalin (Lyrica) is a Schedule V controlled substance precisely because dependence and a recognizable withdrawal syndrome are established. Discontinuation symptoms resemble those of gabapentin and, in some descriptions, mild benzodiazepine withdrawal. Severity tracks with dose and duration.

Tegretol does not produce a classical withdrawal syndrome. The discontinuation considerations are similar to Depakote: bipolar relapse risk and seizure recurrence risk warrant slow tapering. Tegretol's auto-induction of its own metabolism (and many other drug metabolisms) makes drug-interaction considerations during tapering important.

Topiramate (Topamax) is used for seizures, migraine prevention, and off-label mood stabilization. Psychiatric discontinuation symptoms are usually mild, but two scenarios demand a careful taper: people taking it for epilepsy (seizure risk) and people taking it for migraine (rebound headaches).

Trileptal does not produce a classical withdrawal syndrome. The same considerations as other mood stabilizers / anticonvulsants apply: bipolar relapse risk and seizure recurrence risk warrant slow tapering. Generally has fewer drug interactions than Tegretol.

Stimulant discontinuation is more accurately called "rebound" or "crash" than withdrawal in the classical sense. Patients stopping Adderall after chronic use experience a constellation of symptoms driven by dopamine and norepinephrine depletion, but the syndrome is not life-threatening the way benzodiazepine or alcohol withdrawal can be. The rebound is real and uncomfortable, especially fatigue and the return of underlying ADHD symptoms, but it resolves within 1-3 weeks for most patients.

Concerta (methylphenidate ER) has a smoother discontinuation pattern than Ritalin IR because the OROS formulation produces a more gradual serum-level curve. Rebound is generally milder. Otherwise similar pharmacology to Ritalin.

Dexedrine (dextroamphetamine) is a Schedule II amphetamine stimulant. Like other stimulants, stopping produces a "crash" rather than a dangerous physical withdrawal - fatigue, depressed mood, heavy appetite, and oversleeping - usually more pronounced after high-dose or heavy use.

Focalin (dexmethylphenidate) is the active enantiomer of methylphenidate and a Schedule II stimulant. Stopping does not cause a dangerous physical withdrawal, but it can produce a "crash" - fatigue, low mood, increased appetite, and hypersomnia - along with the return of ADHD symptoms. The crash is usually short-lived.

Intuniv (guanfacine) is a non-stimulant ADHD medication that works on blood-pressure-regulating receptors. Its key discontinuation risk is not psychiatric but cardiovascular: stopping abruptly can cause rebound hypertension and a rapid rise in heart rate, similar to clonidine. It must be tapered.

Nuvigil (armodafinil) is the R-enantiomer of modafinil and a Schedule IV agent with low dependence potential. For most patients, stopping mainly returns sleepiness and fatigue. Importantly, though, the armodafinil FDA label cites postmarketing reports of withdrawal symptoms after abrupt cessation or dose reduction following chronic use - so it is not entirely benign, and a taper is prudent after long-term use.

Provigil (modafinil) promotes wakefulness for narcolepsy, shift-work disorder, and sleep apnea (and is used off-label for fatigue). It has low dependence potential compared with classic stimulants, and discontinuation is generally mild - mostly a return of sleepiness and fatigue rather than a true withdrawal syndrome.

Qelbree (viloxazine) is a non-stimulant, non-controlled ADHD medication. Because it is newer, dedicated discontinuation data are limited, but as a non-controlled agent it is not expected to cause dependence or a stimulant-style crash. The most likely effect of stopping is the return of ADHD symptoms.

Ritalin (methylphenidate IR) has a discontinuation pattern similar to amphetamines but tends to be milder because methylphenidate produces less peripheral catecholamine release than amphetamines. The crash is real but usually shorter in duration than Adderall. The short half-life means inter-dose dips are common even during regular use, so the body is somewhat adapted to the rise-and-fall pattern.

Strattera (atomoxetine) is a non-stimulant, non-controlled ADHD medication. It does not produce the dependence or "crash" associated with stimulants, and abrupt discontinuation is generally well tolerated. The main thing patients notice is the return of ADHD symptoms; some report transient fatigue or mood changes.

Vyvanse has a discontinuation pattern similar to Adderall but typically smoother because the prodrug conversion produces a more gradual serum-level curve (no peaks and troughs the way IR amphetamine does). Patients report less pronounced "crash" feeling on stopping Vyvanse compared to Adderall IR, but the underlying rebound physiology is the same.

Buspar (buspirone) has a very mild discontinuation profile and does not produce a meaningful withdrawal syndrome. This is one of the reasons buspirone is preferred over benzodiazepines for chronic anxiety in patients without acute panic.

Clonidine is not habit-forming in the way benzodiazepines or opioids are, but abrupt discontinuation after regular use is genuinely dangerous. Because the drug works by lowering sympathetic (adrenaline) outflow, stopping it suddenly unleashes a rebound surge - most importantly rebound hypertension, sometimes with headache, agitation, sweating, and racing heart. The risk is highest at higher doses, with longer use, and in patients also taking a beta-blocker.

Hydroxyzine (Vistaril, Atarax) is a sedating antihistamine used for anxiety, itching, and sleep. It is not a controlled substance and does not cause dependence, so it has no true withdrawal syndrome. Patients who stop it may notice the return of the anxiety, itch, or insomnia it was treating - rebound of the original symptom, not withdrawal.

Beta-blockers are not addictive, but they are one of the clearest examples of a medication that must not be stopped abruptly. With chronic use the heart up-regulates its beta-receptors; remove the blocker suddenly and those extra receptors are exposed to full adrenaline signaling, producing rebound tachycardia, hypertension, palpitations, and - in people with underlying coronary disease - chest pain or, rarely, a heart attack. This "beta-blocker withdrawal syndrome" is why metoprolol is always tapered.

Prazosin does not produce a classic dependence or withdrawal syndrome - it is not addictive and has no cravings. The practical "withdrawal" experience is twofold: the rapid return of whatever it was controlling (most often trauma-related nightmares and nighttime hyperarousal in PTSD), and, because it lowers blood pressure, the possibility of a blood-pressure rebound when it is stopped. Its evidence for PTSD nightmares is genuinely mixed - some patients respond strongly while a large VA trial was negative - so responses to stopping it vary widely.

Propranolol (Inderal) is used in psychiatry for performance and physical anxiety symptoms, and in medicine for blood pressure, tremor, and migraine. It is not habit-forming, but abrupt discontinuation carries a real cardiovascular risk: rebound tachycardia and hypertension, and in patients with heart disease, rebound angina or even heart attack. For that reason it should be tapered, not stopped suddenly, particularly in anyone with a cardiac history.